A Phase 3 interventional study of Itraconazole 100mg capsules and Itraconazole 200mg tablets in Onychomycosis, sponsored by Stiefel, a GSK Company. Completed at 68 sites in 7 countries. Open to participants aged 16 Years to 75 Years. Per ClinicalTrials.gov, last updated 2017-02-09.
Sponsored by Stiefel, a GSK Company (part of GlaxoSmithKline) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 77 studies in Onychomycosis with a site in United States — 3 open to participants now, 7 under way, 1 of them phase 3. Onychomycosis · United States.
Among the 77 studies in Onychomycosis with a site in United States, this one has the largest enrollment of the 75 interventional ones that give a count, is one of 7 that started in 2006, is one of 14 in phase 3, and was the 3rd registered.
158 studies on the registry are indexed under Onychomycosis; 16 are open to participants now.
Browse Onychomycosis studies →3 of the 77 studies in Onychomycosis with a site in United States are open now. Recruiting first, the newest first:
Nail Genesis LLC · Sites in United States
Ages 18–65
Next Science TM · Sites in United States
Ages 18+
SATO Pharmaceutical Co., Ltd. · Sites in United States
Ages 18–70
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 9 Onychomycosis studies recruiting now, 3 set no upper age limit and 5 stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.
This study: 16 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
77 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 27 · Phase 3 17 · Phase 4 5
First in 2002; this study’s year is marked. 7 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,381 is above the median of 60 across 143 interventional studies indexed under Onychomycosis.
Median enrollment 50 across the 75 interventional studies, 33 across the 2 observational. Of the 62 that completed or were terminated, 23 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
65 of 77 have an industry lead sponsor. The 10 most frequent:
This study is registered under Stiefel, a GSK Company, one of the names counted as GlaxoSmithKline. Under that name alone:
Stiefel, a GSK Company is the lead sponsor of 56 studies on the registry; none are open to participants now.
GlaxoSmithKline has 4 studies filed under Onychomycosis — fewer than ten, so there is no comparison to draw.
1 of the studies in Onychomycosis with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07756671The University of Texas Health Science Center, HoustonPhotodynamic Therapy For Onychomycosis | 2027-06-30 |
Add it to your calendar (.ics) → With an account.
Among the 77 studies in Onychomycosis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Onychomycosis is a common condition accounting for approximately half of all nail disorders. It is most commonly caused by dermatophytes. Itraconazole has been approved for the treatment of onychomycosis in the United States with an approved dosage regimen for the treatment of onychomycosis of the toenail of once daily (QD) treatment with 200mg of itraconazole (two 100 mg capsules) for 12 weeks. Barrier Therapeutics has developed a 200 mg tablet which could be used in a more convenient one-tablet-per-day dosing regimen. This clinical trial will compare the efficacy and safety of this new tablet formulation with itraconazole capsules and placebo.
Onychomycosis is common and accounts for about half of all nail disorders. Usually the cause is due to dermatophytes, either Trichophyton rubrum (71%) or Trichophyton mentagrophytes (20%) but may also be due to yeast infection, usually Candida albicans.
The prevalence of onychomycosis in the United States population as a whole is 13% and is more prevalent in the elderly (60%). Onychomycosis of the toenail recurs and is thought to have a genetic component.
Onychomycosis can result in permanent nail deformity. This disease has a significant impact on the patient's quality of life (e.g., concern with the appearance of the toenails and fingernails, interference with wearing shoes, walking and sports activities).
Itraconazole has been approved for the treatment of onychomycosis in the United States since the mid-nineteen-nineties. The approved dosage regimen for treatment of onychomycosis of the toenail is once daily (QD) treatment with 200 mg of itraconazole (Sporanox®, Janssen Pharmaceutical Products, L.P., Titusville, NJ, USA) for 12 weeks. The approved dosage form is a 100mg capsule. Barrier Therapeutics has developed a 200mg tablet which could be used in a more convenient one-tablet-per-day dosing regimen.
This clinical trial will compare the efficacy and safety of this new tablet formulation with itraconazole capsules and placebo.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Itraconazole 200 mg tablets
Drug: Itraconazole 200mg tablets
Two Itraconazole 100 mg capsules were taken daily.
Drug: Itraconazole 100mg capsules
The itraconazole 200-mg tablets and placebo tablets exactly matched one another and were white to slightly grey in color, were oblong and biconvex in shape, and were melt-extrusion, film-coated.
Drug: Placebo tablets
Subjects took two 100mg capsules once per day after a full meal. The dose dose was taken the day before the Week 12 visit.
Also known as: Sporanox®
Subjects took one 200mg tablet once per day after a full meal. The last dose was taken the day before the Week 12 visit.
Also known as: Onmel
Placebo tablets are the same as the Itraconazole tablets but without the active drug included. Subjects took one tablet once per day after a full meal. The last tablet was taken the day before the Week 12 visit.
Also known as: placebo
Clinical and Mycological Cure of Target Toenail
This study was designed to evaluate the superiority of itraconazole tablets to placebo tablets. Clinical Cure was defined as an IGA score of 0 for the target toenail; Mycological Cure was defined as a negative potassium hydroxide (KOH) exam and a negative culture for dermatophytes of the target toenail.
Time frame: 1 year
Complete Cure - Itraconazole Tablets Compared to Itraconazole Capsules
The primary efficacy endpoint was Compete Cure (consisting of a Clinical Cure and a Mycological Cure) at week 52. In this study, Clinical Cure was defined as an Investigator's Global Assessment (IGA) score of 0 for the target toenail; Mycological Cure was defined as a negative potassium hydroxide (KOH) examination and a negative culture outcome for dermatophytes of the target toenail. The efficacy analyses were conducted to demonstrate the non-inferiority of 1 itraconazole 200-mg tablet to 2 itraconazole 100-mg capsule.
Time frame: 12 months
Clinical Improvement of the Target Toenail
Clinical Improvement consisted of a mycological cure and an Investigator's Global Assessment (IGA) score less than or equal to 1 at week 52. The Investigator's Global Assessment (IGA) assesses the overall severity of onychomycosis on the target toenail and takes into consideration, onycholysis, hyperkeratosis and percent nail involvement. 0 = Clinical Cure: No evidence of onychomycosis. 1 = Clinical Improvement: Minimal evidence of onychomycosis. 2 = Mild: ≤25% dystrophy and/or onycholysis. 3 = Moderate: ≤50% dystrophy with onycholysis. 4 = Severe: \>50% dystrophy with onycholysis.
Time frame: 12 months
Clinical Improvement Compared to Placebo
Clinical Improvement consisted of a mycological cure and an Investigator's Global Assessment (IGA) score less than or equal to 1 at week 52. The Investigator's Global Assessment(IGA)assesses the overall severity of onychomycosis on the target toenail and takes into consideration, onycholysis, hyperkeratosis and percent nail involvement. 0 = Clinical Cure: No evidence of onychomycosis. 1 = Clinical Improvement: Minimal evidence of onychomycosis. 2 = Mild: ≤25% dystrophy and/or onycholysis. 3 = Moderate: ≤50% dystrophy with onycholysis. 4 = Severe: \>50% dystrophy with onycholysis.
Time frame: 12 months
Subjects were recruited from clinics in the US, Canada, South America, Ecuador, Dominican Republic, Panama, and Honduras.
| Milestone | Itraconazole Tablets | Itraconazole Capsules | Placebo Tablets |
|---|---|---|---|
| Started | 593 | 590 | 198 |
| Completed | 517 | 496 | 156 |
| Not completed | 76 | 94 | 42 |
| Withdrew: Non compliance | 1 | 2 | 1 |
| Withdrew: Protocol violation | 2 | 3 | 2 |
| Withdrew: Withdrawal by subject | 14 | 14 | 10 |
| Withdrew: Lack of efficacy | 0 | 0 | 3 |
| Withdrew: Lost to follow-up | 27 | 34 | 14 |
| Withdrew: Administrative decision | 0 | 0 | 1 |
| Withdrew: Physician decision | 0 | 2 | 0 |
| Withdrew: Adverse event | 21 | 31 | 8 |
| Withdrew: Miscellaneous reasons | 11 | 8 | 3 |
This study was designed to evaluate the superiority of itraconazole tablets to placebo tablets. Clinical Cure was defined as an IGA score of 0 for the target toenail; Mycological Cure was defined as a negative potassium hydroxide (KOH) exam and a negative culture for dermatophytes of the target toenail.
| Percentage of participants | Itraconazole Tablets | Placebo Tablets |
|---|---|---|
| Clinical and Mycological Cure of Target Toenail | 22.3 | 1 |
The primary efficacy endpoint was Compete Cure (consisting of a Clinical Cure and a Mycological Cure) at week 52. In this study, Clinical Cure was defined as an Investigator's Global Assessment (IGA) score of 0 for the target toenail; Mycological Cure was defined as a negative potassium hydroxide (KOH) examination and a negative culture outcome for dermatophytes of the target toenail. The efficacy analyses were conducted to demonstrate the non-inferiority of 1 itraconazole 200-mg tablet to 2 itraconazole 100-mg capsule.
| Percentage of participants | Itraconazole Tablets | Itraconazole Capsules | Placebo Tablets |
|---|---|---|---|
| Complete Cure - Itraconazole Tablets Compared to Itraconazole Capsules | 22.3 | 21.7 | 1.0 |
Clinical Improvement consisted of a mycological cure and an Investigator's Global Assessment (IGA) score less than or equal to 1 at week 52. The Investigator's Global Assessment (IGA) assesses the overall severity of onychomycosis on the target toenail and takes into consideration, onycholysis, hyperkeratosis and percent nail involvement. 0 = Clinical Cure: No evidence of onychomycosis. 1 = Clinical Improvement: Minimal evidence of onychomycosis. 2 = Mild: ≤25% dystrophy and/or onycholysis. 3 = Moderate: ≤50% dystrophy with onycholysis. 4 = Severe: \>50% dystrophy with onycholysis.
| percentage of participants | Itraconazole Tablets | Itraconazole Capsules |
|---|---|---|
| Clinical Improvement of the Target Toenail | 33.7 | 29.3 |
Clinical Improvement consisted of a mycological cure and an Investigator's Global Assessment (IGA) score less than or equal to 1 at week 52. The Investigator's Global Assessment(IGA)assesses the overall severity of onychomycosis on the target toenail and takes into consideration, onycholysis, hyperkeratosis and percent nail involvement. 0 = Clinical Cure: No evidence of onychomycosis. 1 = Clinical Improvement: Minimal evidence of onychomycosis. 2 = Mild: ≤25% dystrophy and/or onycholysis. 3 = Moderate: ≤50% dystrophy with onycholysis. 4 = Severe: \>50% dystrophy with onycholysis.
| percentage of participants | Itraconazole Tablets | Placebo Tablets |
|---|---|---|
| Clinical Improvement Compared to Placebo | 33.7 | 2 |
Collected over AEs and SAES are reported for the 12 week treatment period. SAEs are reported for both the treatment & follow-up periods in the Additional Description section.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Itraconazole Tablets - Treatment Period | — | 2/582 (0.3%) | 19/582 (3.3%) |
| Itraconazole Capsules | — | 2/581 (0.3%) | 16/581 (2.8%) |
| Placebo Tablets | — | 2/191 (1%) | 6/191 (3.1%) |
| Itraconazole Tablets - Follow-up Period | — | 10/535 (1.9%) | 19/535 (3.6%) |
| Itraconazole Capsules - Follow-up Period | — | 9/515 (1.7%) | 36/515 (7%) |
| Placebo Tablets - Follow-up Period | — | 1/168 (0.6%) | 8/168 (4.8%) |
| Event | Itraconazole Tablets - Treatment Period | Itraconazole Capsules | Placebo Tablets | Itraconazole Tablets - Follow-up Period | Itraconazole Capsules - Follow-up Period | Placebo Tablets - Follow-up Period |
|---|---|---|---|---|---|---|
| Lung neoplasm malignantNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/582 | 0/581 | 0/191 | 0/535 | 0/515 | 1/168 |
| DiverticulitisInfections and infestations | 0/582 | 0/581 | 1/191 | 0/535 | 0/515 | 0/168 |
| PancreatitisGastrointestinal disorders | 0/582 | 0/581 | 1/191 | 0/535 | 0/515 | 0/168 |
| AnemiaBlood and lymphatic system disorders | 0/582 | 0/581 | 0/191 | 0/535 | 1/515 | 0/168 |
| AppendicitisInfections and infestations | 0/582 | 0/581 | 0/191 | 1/535 | 1/515 | 0/168 |
| Calculus uretericRenal and urinary disorders | 0/582 | 0/581 | 0/191 | 0/535 | 1/515 | 0/168 |
| Cerebrovascular accidentNervous system disorders | 0/582 | 0/581 | 0/191 | 0/535 | 1/515 | 0/168 |
| CholelithiasisHepatobiliary disorders | 1/582 | 0/581 | 0/191 | 0/535 | 1/515 | 0/168 |
| Cardiac failure congestiveCardiac disorders | 0/582 | 0/581 | 0/191 | 0/535 | 1/515 | 0/168 |
| Gastric ulcer haemorrhageGastrointestinal disorders | 0/582 | 0/581 | 0/191 | 0/535 | 1/515 | 0/168 |
| Event | Itraconazole Tablets - Treatment Period | Itraconazole Capsules | Placebo Tablets | Itraconazole Tablets - Follow-up Period | Itraconazole Capsules - Follow-up Period | Placebo Tablets - Follow-up Period |
|---|---|---|---|---|---|---|
| HypoacusisEar and labyrinth disorders | 19/582 | 16/581 | 6/191 | 19/535 | 36/515 | 8/168 |
| Age, Continuous(years) | Itraconazole Tablets | Itraconazole Capsules | Placebo Tablets | Total |
|---|---|---|---|---|
| Mean | 47.1 ± 11.86 | 47 ± 12.67 | 49.2 ± 11.12 | 47.4 ± 12.13 |
| Gender(Participants) | Itraconazole Tablets | Itraconazole Capsules | Placebo Tablets | Total |
|---|---|---|---|---|
| Female | 441 | 440 | 153 | 1034 |
| Male | 152 | 150 | 45 | 347 |
| Race/Ethnicity, Customized(Participants) | Itraconazole Tablets | Itraconazole Capsules | Placebo Tablets | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 7 | 7 | 4 | 18 |
| Asian | 5 | 4 | 2 | 11 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 0 | 1 |
| Black or African American | 48 | 48 | 18 | 114 |
| White | 512 | 493 | 169 | 1174 |
| Unknown or Not Reported | 25 | 41 | 7 | 73 |
| Region of Enrollment(participants) | Itraconazole Tablets | Itraconazole Capsules | Placebo Tablets | Total |
|---|---|---|---|---|
| Panama | 9 | 9 | 3 | 21 |
| United States | 527 | 523 | 176 | 1226 |
| Canada | 23 | 21 | 8 | 52 |
| Ecuador | 6 | 8 | 3 | 17 |
| Honduras | 9 | 9 | 3 | 21 |
| Dominican Republic | 7 | 9 | 2 | 18 |
| South Africa | 12 | 11 | 3 | 26 |
The record gives a start of Jul 2006, a primary completion of Oct 2008 and a completion of Oct 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2012, 3 years 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Itraconazole